drugset / Trial / NCT01733004
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
Timeline
- Start
- 2012-11
- Primary completion
- 2016-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | istiratumab | Monoclonal antibody | — | — |